All AbMole products are for research use only, cannot be used for human consumption.
(R)-Zunsemetinib is the isomer of Zunsemetinib, it can be used as an experimental control. Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor.
| Molecular Weight | 513.92 |
| Formula | C25H22ClF2N5O3 |
| CAS Number | 1640282-44-5 |
| Form | Solid |
| Solubility (25°C) | DMSO 50 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related MAPKAPK2/MAP3K/MAP4K Products |
|---|
| Takinib
Takinib is a potent and selective TAK1 inhibitor with an IC50 of 9.5 nM, more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. |
| GNE-495
GNE-495 is a potent and selective MAP4K4 inhibitor with an IC50 of 3.7 nM. |
| NG25
NG25 is a potent dual TAK1 and MAP4K2 inhibitor with IC50s of 149 nM and 21.7 nM, respectively. |
| PF-06260933
PF-06260933 is a potent inhibitor of MAP4K4 with an IC50 of 3.7 nM, possessing excellent kinome selectivity. |
| MAP4K4-IN-3
MAP4K4-IN-3 is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, and an IC50 of 470 nM in cell assay. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
